IDT Biologika expands investment in German manufacturing capacity
pharmafile | March 28, 2011 | News story | Manufacturing and Production |Â Â Germany, IDT Biologika, vaccinesÂ
IDT Biologika has said it plans to invest around 85 million euros in new production facilities and equipment in Germany by the end of next year.
The vaccines and pharmaceuticals manufacturer will build a new cold storage area, a fill and finishing plant for vaccines and a number of warehouses at its primary facilities at the Dessau-Tornau Pharmapark, according to information issued by the German Federal Ministry of Economics and Technology. The company will also expand its R&D laboratory.
About 160 jobs will be created as a result of the investment programme, which is supported by almost 9 million euros in financial assistance from the federal and state authorities. IDT Biologika currently employs around 880 people at the site.
The company’s chef executive Ralf Pfirmann said at the official ceremony announcing the investment programme – which was attended by German Chancellor Angela Merkel – that the new capacity would set it up to operate more effectively on the global stage.
IDT Biologika develops and markets its own vaccines and pharmaceuticals, as well as providing contract manufacturing and other services to companies across the drug industry. The company says it has already invested around 200 million euros in its manufacturing facilities, which feature two contained manufacturing lines with segregated operations for preparation of cells, virus propagation and virus purification.
The company has been experiencing buoyant growth of late, particularly for its vaccines and biologics manufacturing services. Towards the end of last year said it would install additional filling lines and freeze-drying capacity at Dessau-Tornau Pharmapark with the addition of 80 staff. The latest announcement suggests its expansion plans are accelerating.
Phil Taylor
Related Content
Valneva Scotland supports local cancer charity Team Jak FoundationÂ
Valneva Scotland, the country’s largest vaccine producer, has partnered with local West Lothian-headquartered charity, Team …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
Merck plans to conduct trials for HPV vaccines
Merck, known as MSD outside of the US and Canada, has announced that it is …
